Research
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
-
* Corresponding author: Francesco M Marincola Fmarincola@mail.cc.nih.gov
1 Immunogenetics Section, Department of Transfusion Medicine, Clinical Center National Institutes of Health, Bethesda, MD 20892, USA
2 The Clinical Skin Center of Northern Virginia, Fairfax, VA 22033, USA
3 3M Pharmaceuticals, St Paul, MN 55144-1000, USA
4 Department of Dermatology, National Naval Medical Center, Bethesda, MD 20889, USA
5 Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
6 Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
7 Universita' degli Studi di Milano, Department of Human Morphology, via Mangiagalli, 20133 Milan, Italy
Genome Biology 2007, 8:R8 doi:10.1186/gb-2007-8-1-r8
Published: 15 January 2007Additional files
Additional data file 1:
List of genes previously shown to be associated with the stimulation of various cell types with IFN-α.
Format: TXT Size: 48KB Download file
Additional data file 2:
Extended version of the Materials and methods, providing full disclosure of the methodology used.
Format: DOC Size: 105KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional data file 3:
Complete list of the 637 genes specifically induced by imiquimod treatment based on the statistical approach presented in the text.
Format: TXT Size: 584KB Download file
Additional data file 4:
The mining strategy that was implemented for the preparation of Figure 1c,d.
Format: PPT Size: 107KB Download file
This file can be viewed with: Microsoft PowerPoint Viewer